Does the reverse transcriptase inhibitor, Efavirenz, have a therapeutic effect for crescentic nephritis?

2017 Fiscal Year Final Research Report

• Project/Area Number: 26461238
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Kidney internal medicine
• Research Institution: Juntendo University
• Principal Investigator: Yoshio Shimizu 順天堂大学, 医学部, 先任准教授 (50359577)
• Project Period (FY): 2014-04-01 – 2018-03-31
• Keywords: 半月体形成性腎炎 / レトロトランスポゾン / 実験腎炎 / 逆転写酵素

Outline of Final Research Achievements

We reported that retrotransposon activated a glomerular crescent forming phase in mouse BSA nephritis and a reverse transcriptase inhibitor, Efavirenz, clearly prevented crescent formation. We tried the same protocol to the hL1-EGFP Tg mice which over-express human retrotransposon and show the retrotransposition site by EGFP. By Immunofluorescence, EGFP was not detected in the BSA nephritis tissues. It was suggested that abundant small DNA driven by L1 retrotransposon is a possible inducer of crescent formation.

Free Research Field

臨床腎臓病学